BR112012032463A2 - composição farmacêutica para administração oral. - Google Patents

composição farmacêutica para administração oral.

Info

Publication number
BR112012032463A2
BR112012032463A2 BR112012032463A BR112012032463A BR112012032463A2 BR 112012032463 A2 BR112012032463 A2 BR 112012032463A2 BR 112012032463 A BR112012032463 A BR 112012032463A BR 112012032463 A BR112012032463 A BR 112012032463A BR 112012032463 A2 BR112012032463 A2 BR 112012032463A2
Authority
BR
Brazil
Prior art keywords
oral administration
pharmaceutical composition
weight
parts
phosphodiesterase inhibitor
Prior art date
Application number
BR112012032463A
Other languages
English (en)
Inventor
Hartwig Steckel
Original Assignee
Pharmatech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatech Gmbh filed Critical Pharmatech Gmbh
Publication of BR112012032463A2 publication Critical patent/BR112012032463A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica para administração oral.composiçao farmacêutica para administração oral compreende pelo menos um inibidor de fosfodiesterase e pelo menos um inibidor de fosfodiesterase e pelo menos um álcool de açúcar selecionado do manitol, sorbitol, xilitol, maltitol, lactitol, eritritol, treitol e isomalte, e carbonato de hidrogênio de sódio como excipientes farmacêuticos nas seguintes proporções de peso: inibidor de fosfodiesterase; cerca de 10 a cerca de 150 partes por peso no total; álcool de açúcar: cerca de 50 a cerca de 600 partes por peso no total; e carbonato de hidrogênio de sódio: cerca de 2 a cerca de 100 partes por peso. a composição acima para uso em um método de disfunção erétil masculina com um inìcio acelerado de ação também é revelado.
BR112012032463A 2010-06-24 2011-06-24 composição farmacêutica para administração oral. BR112012032463A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010024866A DE102010024866A1 (de) 2010-06-24 2010-06-24 Formulierung zur Geschmacksmaskierung
PCT/EP2011/003120 WO2011160849A1 (en) 2010-06-24 2011-06-24 Taste-masked pharmaceutical formulation having accelerated onset of action

Publications (1)

Publication Number Publication Date
BR112012032463A2 true BR112012032463A2 (pt) 2016-11-08

Family

ID=44629118

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032463A BR112012032463A2 (pt) 2010-06-24 2011-06-24 composição farmacêutica para administração oral.

Country Status (10)

Country Link
US (1) US20130150370A1 (pt)
EP (1) EP2585041B1 (pt)
JP (1) JP6013329B2 (pt)
BR (1) BR112012032463A2 (pt)
CA (1) CA2802604C (pt)
DE (1) DE102010024866A1 (pt)
EA (1) EA031697B1 (pt)
ES (1) ES2604484T3 (pt)
PL (1) PL2585041T3 (pt)
WO (1) WO2011160849A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109221A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic New effervescent formulations comprising sweetener composition
RU2015132902A (ru) * 2013-01-07 2017-02-09 Сам-А Фарм. Ко., Лтд. Новый быстрорастворимый состав гранул с улучшенной растворимостью
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
MX2022011871A (es) 2020-03-24 2022-12-06 Commscope Technologies Llc Antenas de estación base con un módulo de antena activa y dispositivos y métodos relacionados.
AU2021242222A1 (en) 2020-03-24 2022-11-17 Outdoor Wireless Networks LLC Radiating elements having angled feed stalks and base station antennas including same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1217445B (it) * 1988-04-29 1990-03-22 Altergon Sa Composizione farmaceutiche orosolubili contenti acetilcisteina
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
KR100503949B1 (ko) * 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
DE10328180A1 (de) * 2003-06-16 2005-01-13 Südzucker AG Mannheim/Ochsenfurt Verwendung von Isomalt als Präbiotikum
GB0330255D0 (en) * 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
WO2007060682A1 (en) * 2005-11-28 2007-05-31 Strides Arcolab Limited Effervescent granular formulations of antiretroviral drugs
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
KR100895942B1 (ko) * 2007-05-08 2009-05-07 조선대학교산학협력단 생약 추출물을 함유하는 구강 내 속붕해성 제제 조성물 및그의 제조 방법
WO2009007768A1 (en) * 2007-07-06 2009-01-15 Gumlink A/S Compressed tablet comprising polyol
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
PT2361081T (pt) * 2008-10-14 2016-09-05 Mcneil Ab Forma de dosagem intra-oral multiporção e seu uso

Also Published As

Publication number Publication date
EA201390012A1 (ru) 2013-07-30
EA031697B1 (ru) 2019-02-28
EP2585041A1 (en) 2013-05-01
EP2585041B1 (en) 2016-08-31
PL2585041T3 (pl) 2017-02-28
ES2604484T3 (es) 2017-03-07
JP6013329B2 (ja) 2016-10-25
WO2011160849A1 (en) 2011-12-29
US20130150370A1 (en) 2013-06-13
CA2802604C (en) 2018-11-06
DE102010024866A1 (de) 2011-12-29
CA2802604A1 (en) 2011-12-29
JP2013529605A (ja) 2013-07-22

Similar Documents

Publication Publication Date Title
BR112012032463A2 (pt) composição farmacêutica para administração oral.
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
BR112018008880A8 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
DOP2012000124A (es) Derivados de la cromenona con actividad anti-tumoral
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
CO6400185A2 (es) Formas de dosificación sólida de bendamustina
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
CL2020000747A1 (es) Formulaciones de niraparib.
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
CR20120623A (es) Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona
AR080294A1 (es) Composiciones dirigidas a mejorar la solubilidad y administracion de los compuestos activos de magnolia
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
CO6640216A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
TN2015000135A1 (en) Modified release formulations for oprozomib
BRPI0912112B8 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
AR094146A1 (es) Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
GT201000064A (es) Formulaciones galénicas de alisquireno
AR072889A1 (es) Combinacion coccidicida para uso veterinario
BR112015014180A2 (pt) composições de gel

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16/04/2019.